CN114007693B - 烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途 - Google Patents

烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途 Download PDF

Info

Publication number
CN114007693B
CN114007693B CN202080047245.3A CN202080047245A CN114007693B CN 114007693 B CN114007693 B CN 114007693B CN 202080047245 A CN202080047245 A CN 202080047245A CN 114007693 B CN114007693 B CN 114007693B
Authority
CN
China
Prior art keywords
meibomian gland
nmn
meibomian
composition
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080047245.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114007693A (zh
Inventor
土居雅夫
中嶋毅
町田麻实子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Kyoto University NUC
Original Assignee
Senju Pharmaceutical Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd, Kyoto University NUC filed Critical Senju Pharmaceutical Co Ltd
Publication of CN114007693A publication Critical patent/CN114007693A/zh
Application granted granted Critical
Publication of CN114007693B publication Critical patent/CN114007693B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080047245.3A 2019-06-25 2020-06-24 烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途 Active CN114007693B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019117642 2019-06-25
JP2019-117642 2019-06-25
PCT/JP2020/024916 WO2020262497A1 (ja) 2019-06-25 2020-06-24 ニコチンアミドモノヌクレオチド（ｎｍｎ）およびニコチンアミドリボシド（ｎｒ）の新規用途

Publications (2)

Publication Number Publication Date
CN114007693A CN114007693A (zh) 2022-02-01
CN114007693B true CN114007693B (zh) 2024-07-12

Family

ID=74060627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080047245.3A Active CN114007693B (zh) 2019-06-25 2020-06-24 烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途

Country Status (7)

Country Link
US (1) US20220370484A1 (https=)
EP (1) EP3991795B1 (https=)
JP (1) JP7572007B2 (https=)
CN (1) CN114007693B (https=)
ES (1) ES2989969T3 (https=)
PL (1) PL3991795T3 (https=)
WO (1) WO2020262497A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119792334A (zh) * 2025-02-25 2025-04-11 中国农业大学 组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844561B2 (en) * 2013-03-15 2017-12-19 Washington University Administration of nicotinamide mononucleotide in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127987A2 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
JP2018100222A (ja) * 2015-04-20 2018-06-28 学校法人慶應義塾 角膜損傷の治療剤、改善剤または予防剤
EP3364973A1 (en) * 2015-10-23 2018-08-29 The Jackson Laboratory Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
US20170326161A1 (en) * 2015-12-10 2017-11-16 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof
US10898738B2 (en) * 2016-09-13 2021-01-26 Megumi Tanaka Visual function printing agent, and method for improving visual functions
EP3850954A4 (en) * 2018-09-14 2022-06-08 Megumi Tanaka ANTI-AGEING AGENTS AND PROCESSES
JP6831407B2 (ja) 2019-02-22 2021-02-17 能美防災株式会社 火災受信機

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844561B2 (en) * 2013-03-15 2017-12-19 Washington University Administration of nicotinamide mononucleotide in the treatment of disease

Also Published As

Publication number Publication date
JP7572007B2 (ja) 2024-10-23
EP3991795A1 (en) 2022-05-04
EP3991795A4 (en) 2023-07-19
EP3991795B1 (en) 2024-09-11
PL3991795T3 (pl) 2025-01-13
CN114007693A (zh) 2022-02-01
US20220370484A1 (en) 2022-11-24
JPWO2020262497A1 (https=) 2020-12-30
WO2020262497A1 (ja) 2020-12-30
ES2989969T3 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
CN108350021A (zh) 用于治疗眼科疾病的化合物和制剂
JP2021152032A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US20210008089A1 (en) Compositions and methods for treating an aggregation disease or disorder
KR102537990B1 (ko) 스테로이드 용량의 감소 및 염증과 자가면역 질환의 치료를 위한 칸나비디올
TW201038544A (en) Anti-neurodegenerative diseases agents
US11654140B2 (en) Treatment of ocular inflammatory diseases using laquinimod
CN105517546A (zh) 治疗脆性x综合征及相关疾病的方法
KR20200044873A (ko) 안구 제약학적 조성물
JP2024539929A (ja) 頂端側ナトリウム依存性胆汁酸輸送体阻害剤（ａｓｂｔｉ）の投薬方法
CN114007693B (zh) 烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途
US20230277491A1 (en) Pharmaceutical combination comprising glycolic acid and l-alanine
US20220288096A1 (en) Compositions and methods for treating an aggregation disease or disorder
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
CN105566100A (zh) 一种苯乙烯酸类化合物，包含其的组合物及其应用
WO2016068278A1 (ja) 水晶体硬化抑制剤
US20140228332A1 (en) Method for enhancing the secretion of glp-1 using bitter compounds
EP1859795A1 (en) Therapeutic agent for ophthalmic disease
Laitinen et al. Rapid elimination of suprachoroidally injected small molecule drugs into the systemic blood circulation
HK40112370A (zh) 顶端钠依赖型胆酸转运蛋白抑制剂(asbti)的给药方法
HK40111552A (zh) 用於治疗干眼综合征的包含瑞可黄酮的滴眼剂组合物及其制备方法
HK40113179A (zh) 以回肠胆汁酸转运蛋白(ibat)抑制剂治疗以增加无事件存活期(efs)
Menclova et al. PP-026 Oral viscous budesonide suspension for the treatment of eosinophilic esophagitis
HK1209335B (en) Baclofen and acamprosate based therapy of macular degeneration disorders
Banz et al. Calming the Ocular Storm

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant